Additional file 2: Figure S2. of FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Abstract

FRAX597 and gemcitabine decreased Ki67 staining on orthotopic pancreatic tail tumours. Pan02 murine pancreatic tumours from the orthotopic pancreatic tail tumour model treated with saline (control; CT), FRAX597 (FRAX), gemcitabine (Gem), or FRAX597 and gemcitabine (Gem + FRAX) at the doses given in the Materials and Methods section, were fixed and stained for the proliferative marker, Ki67. Three representative images were taken from each treatment group. (PPTX 2275 kb